GlobeNewswire by notified

Eurocastle Releases First Quarter 2023 Interim Management Statement and Announces Annual General Meeting to be held on 14 June 2023

Share

EUROCASTLE INVESTMENT LIMITED


Contact:        
Oak Fund Services (Guernsey) Limited
Company Administrator
Attn: Hannah Crocker
Tel: +44 1481 723450        

Eurocastle Releases First Quarter 2023Interim Management Statementand
Announces Annual General Meeting to be held on 14 June 2023

Guernsey, 15 May 2023 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today has released its interim management statement for the quarter ended 31 March 2023 and announced it will hold its Annual General Meeting on 14 June 2023.

  • ADJUSTED NET ASSET VALUE (“NAV”)1 of €10.3 million, or €10.34 per share2, up €0.01 per share vs. Q4 2022 primarily due to valuation movements on its real estate fund investments.



Q4 2022 Q1 Cash Movement Q1 FV MovementQ1 2023 NAV
€’m€ p.s.€’m€ p.s.€’m€ p.s.€’m€ p.s.
Real Estate Funds 0.60.63--0.00.010.60.64
Net Corporate Cash317.117.15(0.2)(0.17)(0.2)(0.19)16.716.79
Legacy German Tax Asset4.64.670.20.17--4.84.84
IFRS NAV22.422.45--(0.2)(0.18)22.222.27
Additional Reserves4  (12.1)(12.12)--0.20.19(11.9)(11.93)
Adjusted NAV



10.3

10.33

-

-

0.0

0.01

10.3

10.34

Ordinary shares outstanding995,555995,555












As at 31 March 2023, the Company’s remaining assets comprise:

  1. Two Real Estate Fund Investments with an NAV of €0.6 million, or €0.64 per share, where the underlying apartments are now all sold with both funds currently in liquidation.

  2. €16.7 million, or €16.79 per share, of net corporate cash3

BUSINESS HIGHLIGHTS:

  • Real Estate Funds – With all units in both funds having been sold, the funds are focused on their respective liquidations. In April, Eurocastle received €0.5 million, or over 80% of its Q1 NAV in these investments.

  • New Investment Strategy – The Company established a subsidiary in Luxembourg through which it shortly expects to commence investing. The Company has identified several opportunities in Greece to acquire real estate assets that are currently collateral to defaulted claims or owned by banks as a consequence of a repossession process.

ANNUAL GENERAL MEETING

The Company will hold its Annual General Meeting on Wednesday, 14 June 2023, at the Company’s registered office at 2:00 pm Guernsey time (3:00 pm CET). Notices and proxy statements will be posted on 30 May 2023 to shareholders of record at close of business on 26 May 2023.


NOTICE: This announcement contains inside information for the purposes of the Market Abuse Regulation 596/2014.

ADDITIONAL INFORMATION

For investment portfolio information, please refer to the Company’s most recent Financial Report, which is available on the Company’s website (www.eurocastleinv.com).

Terms not otherwise defined in this announcement shall have the meaning given to them in the Circular.

ABOUT EUROCASTLE

Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. On 8 July 2022, the Company announced the relaunch of its investment activity and is currently in the early stages of pursuing its new strategy by initially focusing on opportunistic real estate in Greece with a plan to expand across Southern Europe. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

FORWARD LOOKING STATEMENTS

This release contains statements that constitute forward-looking statements. Such forward-looking statements may relate to, among other things, future commitments to sell real estate and achievement of disposal targets, availability of investment and divestment opportunities, timing or certainty of completion of acquisitions and disposals, the operating performance of our investments and financing needs. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may”, “will”, “should”, “potential”, “intend”, “expect”, “endeavour”, “seek”, “anticipate”, “estimate”, “overestimate”, “underestimate”, “believe”, “could”, “project”, “predict”, "project", “continue”, “plan”, “forecast” or other similar words or expressions. Forward-looking statements are based on certain assumptions, discuss future expectations, describe future plans and strategies, contain projections of results of operations or of financial condition or state other forward-looking information. The Company’s ability to predict results or the actual effect of future plans or strategies is limited. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, its actual results and performance may differ materially from those set forth in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and other factors that may cause the Company’s actual results in future periods to differ materially from forecasted results or stated expectations including the risks regarding Eurocastle’s ability to declare dividends or achieve its targets regarding asset disposals or asset performance.


1 In light of the Realisation Plan announced in November 2019, the Adjusted NAV as at 31 March 2023 reflects additional reserves for future costs and potential liabilities, which have not been accounted for under the IFRS NAV. No commitments for these future costs and potential liabilities existed as at 31 March 2023. IFRS NAV as at 31 March 2023 was €22.2 million or, €22.27 per share.
2 Per share calculations for Eurocastle throughout this document are based on 995,555 shares, unless otherwise stated.
3 Reflects corporate cash and cash equivalents net of accrued liabilities and other assets where treasury investments mainly comprise notice accounts and Italian Government Bonds.
4 Reserves that were put in place when the Company realised the majority of its investment assets in December 2019 in order for the Company to continue in operation and fund its future costs and potential liabilities. These reserves are not accounted for under IFRS.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release

Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern

ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release

SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and

Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342

HiddenA line styled icon from Orion Icon Library.Eye